Designed multiple ligands are compounds with a well-defined multi-target profile to distinguish them from nonselective (or “dirty”) drugs. They are of particular relevance in highly complex diseases such as those related to metabolism and the central nervous system (CNS).
Thus the aim of this project is to incorporate two activities into a single lead molecule by linking, fusing or merging two pharmacophore groups of PPAR, cannabinoid, and opioid ligands and study them for obesity, pain, and other complex diseases.